Diabetic foot neuropathy new drug: FDA's first capsaicin patch Qutenza (8%), paste once, the effect lasts 3 months!

July 23, 2020 /PRNewswire/ -- Gr?nenthal has announced that its U.S. subsidiary, Averitas Pharma, has received FDA approval for 8% of Qutenza (capsaicin, capsaicin) patch, which is used in adult patients to treat neuropathy associated with diabetic neuropathy (DPN) in adult patients.
Qutenza is an external, non-systemic, non-opioid painkiller offered as a patch, the first and only treatment to deliver prescription-strength capsaicin directly to the skin.
DPN-related neuropathic pain, also known as diabetic nerve pain, is a progressive and debilitating complication of diabetes that will affect about 5 million people in the United States by 2020 and is expected to double by 2030.
patients with diabetic nerve pain usually experience numbness and tingling, with the lower limbs being the most severely affected.
In 2009, the United States approved the use of Qutenza (capsaicin) 8% patch for the treatment of neuropathic pain caused by neuropathy after shingles.
approval of the new indications will provide a much-needed non-opioid treatment option for diabetic foot patients who have experienced DPN torture.
Qutenza provides doctors with a different approach to effectively treating neuropathological pain associated with DPN in the foot.
Qutenza is a specially formulated patch that delivers prescription-strength capsaicin directly to the skin during outpatient surgery.
capsaicin can reverse and de-functionalize the TRPV1 (instantaneous receptor potential vanilla acid subtype 1) receptor, which plays a key role in pain signal conduction.
Qutenza single-time local therapy provides lasting pain relief for up to three months, and the drug has no known drug interactions.
most common adverse reactions include reactions at the drug site, such as erythema, pain and itching.
reactions in most applications are short-lived and self-limiting. "Diabetic peripheral neuropathy is a painful complication of diabetes that can have a significant impact on the daily lives of patients," said Jan Adams, chief scientific officer of the
.
we believe Qutenza will bring these patients a much-needed non-opioid treatment option.
in the United States, Qutenza's expansion of indications is an exciting milestone in our efforts to bring Qutenza to more patients around the world.
" () Original source: Gr?nenthal and Averitas Pharma Announce U.S. FDA approval of QUTENZA® for the treatment of the patient syced of Neuropathic Pain Associates with Beau Bo Neuropathy of the Feet.